1. Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. bmj 2020; 23 (5): 371.## [DOI:10.1136/bmj.m3862] [PMID]

2. Ripa M, Galli L, Poli A, Oltolini C, Spagnuolo V, Mastrangelo A, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clinical Microbiology and Infection 2021; 27(3): 451-7. ##

3. Rawson TM, Moore LS, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clinical Infectious Diseases 2020; 71(9): 2459-68. ## [DOI:10.1093/cid/ciaa530] [PMID] []

4. Russell CD, Fairfield CJ, Drake TM, Turtle L, Seaton RA, Wootton DG, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. The Lancet Microbe 2021; 2(8): e354-e65. ## [DOI:10.2139/ssrn.3786694]

5. Casalini G, Giacomelli A, Ridolfo A, Gervasoni C, Antinori S. Invasive fungal infections complicating COVID-19: a narrative review. Journal of Fungi 2021; 7(11): 921. ## [DOI:10.3390/jof7110921] [PMID] []

6. Fortún J, Martín‐Dávila P, Moreno S, De Vicente E, Nuño J, Candelas A, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transplantation 2002; 8(11): 1065-70. ## [DOI:10.1053/jlts.2002.36239] [PMID]

7. Seagle EE, Jackson BR, Lockhart SR, Georgacopoulos O, Nunnally NS, Roland J, et al. The landscape of candidemia during the coronavirus disease 2019 (COVID-19) pandemic. Clinical Infectious Diseases 2022; 74(5): 802-11. ## [DOI:10.1093/cid/ciab562] [PMID]

8. Kayaaslan B, Eser F, Kaya Kalem A, Bilgic Z, Asilturk D, Hasanoglu I, et al. Characteristics of candidemia in COVID‐19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non‐COVID‐19 patients. Mycoses 2021; 64(9): 1083-91. ## [DOI:10.1111/myc.13332] [PMID] []

9. Bayram N, Ozsaygılı C, Sav H, Tekin Y, Gundogan M, Pangal E, et al. Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. Japanese Journal of Ophthalmology 2021; 65(4): 515-25. ## [DOI:10.1007/s10384-021-00845-5] [PMID] []

10. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases 2020; 71(15): 762-8. ## [DOI:10.1093/cid/ciaa248] [PMID] []

11. Wickersham R, Novak K, Schweain S. Drug facts and comparisons. 60thed. Amazone; 2006; 470-81##

12. McEvoy G, Miller J, Snow E. AHFS 2010 Drug Information. Bethesda, Maryland; 2010; 218-30.

13. Chrousos GP, Katzung B, Trevor A . Basic and clinical pharmacology. New York: McGraw-Hill Medical; 2018; 355-67. ##

14. Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia 2020; 185(4): 599-606. ## [DOI:10.1007/s11046-020-00462-9] [PMID] []

15. Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar J. Invasive fungal diseases during COVID-19: we should be prepared. Elsevier; 2020. p. 100971. ## [DOI:10.1016/j.mycmed.2020.100971] [PMID] []

16. Fayemiwo S, Adegboro B. Invasive fungal infections and COVID-19: a review. African Journal of Clinical and Experimental Microbiology 2022; 23(1): 14-21. ## [DOI:10.4314/ajcem.v23i1.2]

17. van Arkel AL, Rijpstra TA, Belderbos HN, Van Wijngaarden P, Verweij PE, Bentvelsen RG. COVID-19-associated pulmonary aspergillosis. American Journal of Respiratory and Critical Care Medicine 2020; 202(1): 132-5. ## [DOI:10.1164/rccm.202004-1038LE] [PMID] []

18. Gold JA, Adjei S, Gundlapalli AV, Huang Y, Chiller T, Benedict K, et al. Increased Hospitalizations involving fungal infections during COVID-19 Pandemic, United States, January 2020-December 2021. Emerging Infectious Diseases 2023; 29(7): 1433-7. ## [DOI:10.3201/eid2907.221771]

19. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Frontiers in Immunology 2020; 1(5): 827. ## [DOI:10.1101/2020.02.18.20024364]

20. Singh V, Prasad A, Panda PK, Totaganti M, Tyagi AK, Thaduri A, et al. Mixed invasive fungal infections among COVID-19 patients. Current Medical Mycology 2021; 7(4): 19. ## [DOI:10.1101/2021.08.09.21261555]

21. Egger M, Bussini L, Hoenigl M, Bartoletti M. Prevalence of COVID-19-associated pulmonary aspergillosis: critical review and conclusions. Journal of Fungi 2022; 8(4): 390. ## [DOI:10.3390/jof8040390] [PMID] []

22. Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux JP, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. The Lancet Microbe 2022; 3(7): e522-43. ## [DOI:10.1016/S2666-5247(21)00237-8] [PMID]

23. Gangneux JP, Reizine F, Guegan H, Pinceaux K, Le Balch P, Prat E, et al. Is the COVID-19 pandemic a good time to include Aspergillus molecular detection to categorize aspergillosis in ICU patients? A monocentric experience. Journal of Fungi 2020; 6(3): 105. ## [DOI:10.3390/jof6030105] [PMID] []

24. Salehi M, Ahmadikia K, Mahmoudi S, Kalantari S, Jamalimoghadamsiahkali S, Izadi A, et al. Oropharyngeal candidiasis in hospitalised COVID‐19 patients from Iran: Species identification and antifungal susceptibility pattern. Mycoses 2020; 63(8): 771-8. ## [DOI:10.1111/myc.13137] [PMID] []

25. Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerging Infectious Diseases 2021; 27(9): 2349. ## [DOI:10.3201/eid2709.210934] [PMID] []